Dishman Pharma

Sharmila Joshi of sharmilajoshi.com advises exiting Dishman Pharmaceuticals.

Stocks in the news: Tata Steel, Golden Tobacco, Lupin, Capital First, IRB Infra

Tata Steel | Golden Tobacco | JSW Steel | Edelweiss | Emami Paper | Shree Cement | Dishman Pharma | IRB Infra | Lupin | Umang Dairies | Future Enterprise | Ganesh Ecosphere and Capital First are stocks, which are in news today.

Bull's Eye: Buy India Cements, Ashok Leyland, Dishman Pharma, BEML; sell Dish TV

Gaurav Ratnaparkhi of Sharekhan advises buying India Cements with a target of Rs 223.

Bull's Eye: Buy GSPL, Gayatri Projects, Natco Pharma, REC, Dredging Corp

Ashish Kyal of Waves Strategy Advisors advises buying Natco Pharma with a target of Rs 965.

Buy STC, Ceat, Dishman Pharma: Ashwani Gujral

Ashwani Gujral of ashwanigujral.com suggests buying STC, Ceat and Dishman Pharma.

Banks, local cues help Nifty reclaim 9,100; Sensex closes 172 points higher

Banks saw a rally on the back of possible deal buzz, with Kotak Mahindra Bank calling for a press briefing on Wednesday. Encouraging local news on the GST front and rally in Asian markets helped D-Street end in green.

Top buzzing midcap stocks to trade on March 28

Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- Bharti Airtel, Bharti Infratel, Dishman Pharma, Technofab Engineering, Balaji Telefilms and Dilip Buildcon.

Stocks in news: Tata Steel, DHFL, Dishman Pharma, SKS Micro

Stocks in news: Tata Steel | Sanghi Industries | Bhushan Steel | Dewan Housing | PFC | Dhanlaxmi Bank | SKS Micro and Dishman Pharma are stocks, which are in news today.

Dishman Pharma consolidated Sep '15 sales at Rs 381.16 crore

Dishman Pharmaceuticals & Chemicals has reported a consolidated total income from operations of Rs 381.16 crore and a net profit of Rs 36.50 crore for the quarter ended Sep '15

Nifty ends below 7850 ahead of F&O expiry, Sensex up 171pts

IDBI gained 12 percent. MD and CEO Kishor Kharat told CNBC-TV18 that while he hasn't heard any news of an Axis Bank like structure for IDBI Bank, but it would certainly be a welcome move. Dishman Pharma gained 8 percent after the company announced a tie-up that makes them exclusive supplier of the API for Janssen's tuberculosis drug - Sirturo.

Dishman Pharma consolidated Jun '15 sales at Rs 400.55 crore

Dishman Pharmaceuticals & Chemicals has reported a consolidated total income from operations of Rs 400.55 crore and a net profit of Rs 37.76 crore for the quarter ended Jun '15

Dishman Pharma consolidated Mar '15 sales at Rs 423.67 crore

Dishman Pharmaceuticals & Chemicals has reported a consolidated total income from operations of Rs 423.67 crore and a net profit of Rs 38.77 crore for the quarter ended Mar '15

Dishman Pharma consolidated Dec '14 sales at Rs 389.68 crore

Dishman Pharmaceuticals & Chemicals has reported a consolidated total income from operations of Rs 389.68 crore and a net profit of Rs 24.03 crore for the quarter ended Dec '14

Dishman Pharma consolidated Sep '14 sales at Rs 399.13 crore

Dishman Pharmaceuticals & Chemicals has reported a consolidated total income from operations of Rs 399.13 crore and a net profit of Rs 33.36 crore for the quarter ended Sep '14

Dishman Pharma consolidated Dec '13 sales at Rs 314.26 crore

Dishman Pharmaceuticals & Chemicals has reported a sales turnover of Rs 314.26 crore and a net profit of Rs 15.16 crore for the quarter ended Dec '13

Dishman Pharma may test Rs 105-110: Sudrashan Sukhani

Sudarshan Sukhani of s2analytics.com is of the view that Dishman Pharmaceuticals & Chemicals may test Rs 105-110.

Buy Ceat, TRF, Arvind, Dishman Pharma: Rakesh Gandhi

Rakesh Gandhi, independent technical analyst recommends buying Dishman Pharmaceuticals & Chemicals with a target of Rs 104.50 and Arvind with a target of Rs 141.75.

May surpass FY14 rev guidance by 5%: Dishman Pharma

JR Vyas, CMD, Dishman Pharma said the sale of SEZ land is likely to be concluded in the next fiscal.

Buy Dishman Pharma, TVS Motor advises Systematix Shares

Systematix Shares is bullish on Dishman Pharmaceuticals & Chemicals, TVS Motor Company and has recommended to buy both the stocks for target price of Rs 93 and Rs 59.50 respectively, in its research report dated December 18, 2013.

Bull's Eye: Buy Suven Life, Dishman, Idea; sell Arvind, OBC

Manav Chopra of Nirmal Bang advises buying CESC for a target price of Rs 405 and SREI Infrastructure for a target price of Rs 24.2.

Dishman Pharma consolidated Sep '13 sales at Rs 354.95 crore

Dishman Pharmaceuticals & Chemicals has reported a sales turnover of Rs 354.95 crore and a net profit of Rs 42.28 crore for the quarter ended Sep '13

Stocks in news: Tata Motors, HCL Tech, IOC, Elder Pharma

Rajshree Sugars | 3M India | GTL Infra | Future Retail | Kalpataru Power | Magma Fincorp | Glenmark Pharma | Dishman Pharma | Sesa Sterlite | IDFC | Tata Motors | HCL Technologies | SpiceJet | Religare Enterprises | IOC | MCX | Jagaran Prakashan and Elder Pharma are stocks, which are in the news today.

Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx

Arpit Vyas, MD of Dishman Pharma presents his views on the company‘s quarterly earnings, in an interview to CNBC-TV18.

Dishman Pharma slips 7% on income tax survey woes

JR Vyas, chairman and MD said that tax men quizzed the company over tax exemption for a sale of land from Dishman SEZ to Dishman Pharma for Rs 42 crore. The exemption under (section) 80 existed then, but now the I-T is demanding tax for the same, Vyas tells CNBC-TV18.

Expect to cut debt by Rs 70-80 cr this year: Dishman Pharma

Arpit Vyas, MD, Dishman Pharma aims at working with EBITDA margins not below USD 25-30 percent and expects to pare down the company debt by Rs 70-80 crore this calendar year.